VLST Corp.
Seattle
Washington
United States
15 articles about VLST Corp.
-
VLST Corp., After Nine Years and $50 Million, Sells Assets and Winds Down
8/7/2013
-
VLST Corp. Cuts Scientific Group as Focus Shifts to Clinical Trials
9/27/2012
-
VLST Corp. Scoops Up Antibody for Cancer From Pfizer Inc.
8/31/2012
-
Theraclone Sciences, Inc. and VLST Corp. Creators Form V-Gene
1/27/2012
-
VLST Corp. Appoints Brian Blackman as Vice President, Finance & Administration
6/13/2011
-
AnaptysBio, Inc. Announces Collaboration with VLST Corp. to Generate Novel Antibody Therapeutics
4/5/2010
-
VLST Corp. Cuts Jobs To Preserve Cash, Still Feeding Novo Nordisk A/S Pipeline
12/22/2009
-
VLST Corp. and Novo Nordisk, Inc. Announce Collaboration Agreement to Develop Therapeutics for Autoimmune and Inflammatory Disorders
12/17/2008
-
VLST Corp. Appoints Internationally Recognized Researcher Paul J. Carter, Ph.D. as Chief Scientific Officer
7/2/2008
-
VLST Corp. Announces Board and Executive Management Appointments
2/13/2008
-
VLST Corp. Names Consuelo M. Blosch, M.D., Vice President of Clinical and Regulatory and Dan Allison, Ph.D., Sr. Director of Therapeutic Design
9/17/2007
-
VLST Corp. Raises $55 Million Series B Financing
6/16/2006
-
VLST Corp. Names Julie M. Eastland As Chief Financial Officer
3/6/2006
-
VLST Corp. Names Julie M. Eastland As Chief Financial Officer
3/3/2006
-
VLST Corp. And Accelerator Corporation Name Martin A. Simonetti President And Chief Executive Officer
1/6/2006